SCIENTIFIC REPORTS

OPEN

Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis

Received: 01 March 2016
Accepted: 11 August 2016
Published: 06 September 2016

Longhao Zhang¹, Qiyan Chen², Ling Li¹, Joey S. W. Kwong¹, Pengli Jia¹, Pujiang Zhao¹, Wen Wang¹, Xu Zhou¹, Mingming Zhang¹ & Xin Sun¹

Alpha-glucosidase inhibitors (AGIs) was reported to be associated with several rare adverse hepatic events, but with inconsistent results. We aimed to investigate the risk of hepatotoxicity associated with the use of AGIs in patients with type 2 diabetes mellitus (T2DM), and performed a systematic review and meta-analysis. Fourteen studies ($n = 2881$) were eligible, all of which were RCTs. Meta-analysis of data regarding elevation of more than 3-fold the upper limit of normal (ULN) of AST and ALT showed statistically significant differences between AGIs treatment versus control (OR 6.86, 95% CI 2.50 to 18.80; OR 6.48, 95% CI 2.40 to 17.49). Subgroup analyses of elevation of more than 1.8-fold ULN of AST and ALT by dose of AGIs showed differential effects on AST and ALT (AST: OR 0.38 vs 7.31, interaction $P = 0.003$; ALT: OR 0.32 vs 4.55, interaction $p = 0.02$). Meta-analysis showed that AGIs might increase the risk of hepatotoxicity, and higher dose appeared to be associated with higher risk of hepatotoxicity. However, the evidence is limited with surrogate measures (i.e. ALT and AST), and no clinically important adverse events were observed.

Alpha-glucosidase inhibitors (AGIs) are commonly used oral hypoglycemic drugs, especially in the patient population from East Asia^{1–3}. The guideline of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommended the use of AGIs as a potentially first-line agent or in combination with other antihyperglycemic drugs⁴.

AGIs has proven similarly efficacious as other commonly used antidiabetes agents^{5–7}. A recent large trial¹ showed that acarbose is similar to metformin in terms of efficacy, and supports a viable choice for initial therapy in patients with newly diagnosed type 2 diabetes. Additionally, AGIs do not increase body weight, rarely cause hypoglycemia; and have minimal drug-drug interactions^{1,7,8}.

Meanwhile, AGIs was reported to be associated with several rare adverse hepatic events^{9–11} and increase liver enzyme levels^{12–18}. The causal relationship, however, has not been established⁹, and the magnitude of effect on the increase of liver enzyme levels remains unclear. Because these issues are often treated as adverse effects issues, and the hepatic adverse events, if any, are usually rare, individual trials are not adequate to address these important clinical questions. A meta-analysis – in which multiple studies are pooled – may offer opportunity to detect a small but clinically important difference.

Thus, we carried out a systematic review of randomized controlled trials and observational studies to assess the association between hepatotoxicity and AGIs. We hypothesized that hepatotoxicity would be more frequently manifested in AGIs as opposed to no use.

Results

Figure 1 showed the study selection process. We acquired 5,318 reports. After title and abstract screening, 178 were potentially eligible (including 159 potentially relevant RCTs and 19 potentially relevant observational studies^{19–37}). Ultimately, 14 RCTs^{13–18,38–45} involving 2881 patients, proved eligible, and no observational studies were included.

¹Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China.

²West China School of Public Health, Sichuan University, Chengdu 610041, China. Correspondence and requests for materials should be addressed to M.Z. (email: mingming-zhang@163.com) or X.S. (email: sunx79@hotmail.com)

Figure 1. Flow chart of article selection. *Data form ClinicalTrial.gov.

Study characteristics. Table 1 summarized the characteristics of included trials. Of those 14 RCTs, 10 (64.3%) were multicenter studies, and three (24.3%) were international trials. The length of follow-up ranged from 12 to 52 weeks. The trials enrolled 65 to 420 patients (total 3175), with a mean age range of 55.5 to 63.0, mean BMI 24.2 to 31.5 kg/m², mean baseline HbA1c 6.5 to 9.6%, mean fasting plasma glucose 8.8 to 12.2 mmol/L, and mean duration of diabetes 1.8 to 12.2 years. Twelve tested acarbose, one tested miglitol and one tested voglibiose. Twelve tested AGIS monotherapy, and two used AGIS as add-on or combination treatment.

Risk of bias assessment. Table S1 (Appendix 2) summarized the risk of bias of included studies. The general reporting of methodological issues was suboptimal in those trials. Of those trials that provided adequate methodological details, two (14.2%) adequately generated random sequence; one (7.1%) adequately concealed allocation; 9 (64.3%) blinded patients, caregivers, and outcome assessors. Incomplete rate of all patient ranged from 0 to 25.6%. The treatment groups of included trials were generally balanced with respect to demographics and clinical characteristics. Ten (71.4%) studies were industry funded.

Risk of hepatotoxicity. Of the 14 RCTs reporting outcomes of interest, three^{18,40,44} explicitly stated no liver adverse events (AEs). Eleven studies reported changes of liver enzyme levels. We thus carried out meta-analyses regarding the high-grade (1.8-fold and 3-fold of ULN) AST and ALT elevation.

High-grade AST elevation. Six trials^{13,15,39,43–45} reported 17 cases elevations of more than 1.8-fold ULN of AST levels in 1505 patients who used at least one medication (raw event rate 1.0%). Pooling of these trials showed no statistically significant difference in the risk of elevations more than 1.8-fold ULN of AST levels between AGIs treatment and control (Peto OR: 2.12, 95% CI 0.80 to 5.60; I-square = 51%). The subgroup analyses by type of AGIs agent, type of control, length of follow-up and mode of treatment suggested no apparent differences, but differential effects were present among the varying doses of AGIs (AGIs ≤ 100 mg t.i.d. (Peto OR: 0.32, 95%CI 0.05 to 1.97) vs >100 mg t.i.d. (Peto OR: 7.31, 95%CI 2.05 to 26.08); interaction P = 0.003) (Fig. 2). The sensitivity analysis using alternative effect measures (OR vs RR), analysis models (random vs fixed) and pooling methods (Peto vs. Mantel-Hanszel method) did not show important changes in the pooled effects.

Seven trials^{13–18,44} reported 16 cases of elevation of more than 3-fold ULN of AST levels occurred in 1603 patients who used at least one medication (raw event rate 1.0%). Pooling of these trials showed an increased risk of elevations more than three times ULN of AST levels in patients taking AGIs versus control (Peto OR: 6.86,

Author(year)	International study	No of Groups	No of countries involved	No of study sites	Total No of patients	Follow up (weeks)	No (%) male	Mean age (years)	Mean BMI (kg/m ²)	Mean HbA1c (%)	Mean FPG (mmol/L)	Mean diabetes duration (years)	Background medications	AGLS group	Control group
Coniff (1994) ¹³	NR	2	1	12	211	24	94(48.5)	55.80	31.5*	NR	11.50	0.5-33&	None	Acarbose 100 mg to 300mg t.i.d.	Placebo
Coniff (1995) ¹⁴	Yes	4	NR	NR	290	16	166(57.2)	55.49	30.50	8.96	12.09	5.50	None	Acarbose 100 mg to 300mg tid	Placebo
Coniff (1995a) ¹⁵	NR	4	NR	NR	255	30	NR	55.90	29.86	6.92	12.18	5.37	None	Acarbose 200mg t.i.d.	placebo Tolbutamide
Coniff (1995b) ¹⁶	NR	2	1	12	219	24	NR	NR	NR	6.51	9.65	NR	None	Acarbose 50mg to 300 mg t.i.d.	Placebo
Costa (1997) ³⁸	No	2	1	7	65	24	22(33.8)	60.87	28.12	8.91	10.27	NR	None	Acarbose 100mg t.i.d.	Placebo
Fischer (1998) ³⁹	Yes	5	5	NR	420	24	222(52.9)	56.62	27.32	7.41^	NR	1.80	None	Acarbose 25mg to 200mg t.i.d.	Placebo
Gentile (2001) ⁴⁰	No	2	1	NR	100	26	NR	NR	27.8	8.80	8.78	9.0	None	Acarbose 100mg t.i.d.	Placebo
Hoffmann (1997) ⁴¹	No	3	1	4	96	24	30(31.2)	58.33	26.70	9.57	8.87	2.92	None	Acarbose 100mg t.i.d.	Metformin
Hwu (2003) ⁴²	Yes	2	2	6	111	18	55(49.5)	56.32	24.15	9.50	10.54	12.21	None	Acarbose 100mg t.i.d.	Placebo
Iwamota (2010) ¹⁸	No	2	1	51	380	12	251(66.1)	59.14	24.54	7.55	9.00	5.35	None	Voglibose 0.2mg t.i.d.	Vildagliptin
Johnston (1994) ⁴³	No	3	1	12	192	20	109(56.8)	58.33	30.32	8.85	11.04	8.64	None	Miglitol 50 mg to 100mg t.i.d.	Placebo
Lam (1998) ¹⁷	No	2	1	3	89	24	39(43.8)	57.36	24.45	9.45	10.46	10.15	None	Acarbose 100mg t.i.d.	Placebo
Rosenstock (1998) ⁴⁴	NR	2	1	NR	168	24	78(52.7)	56.55	29.70	8.32	9.76	7.50	Metformin	Acarbose 50 mg to 100 mg t.i.d.	Placebo
Scorpiglione (1999) ⁴⁵	No	2	1	17	250	52	123(49.2)	62.99	31.5	8.55	11.47	10.45	Standard care	Acarbose 100mg t.i.d.	No additional drugs

Table 1. Characteristics of studies of AGIs treatment in patients with type 2 diabetes mellitus. * = Median; & = full range; ^ = Geometric mean; NR = not report.

95% CI 2.50 to 18.80; I-square = 0%) (Fig. 3). The subgroup analyses showed no any significant differences. The sensitivity analysis did not show important changes in pooled effects. In one of sensitivity analyses, we removed studies with potential overlap of study population across publications (e.g. Chniff 1995a and Chniff 1995b); the pooled estimates showed no significant change.

High-grade ALT elevation. Seven trials^{13,14,39,41,43–45} reported 18 cases elevations more than 1.8 times ULN of ALT levels occurred in 1601 patients who used at least one medication (raw event rate 1.1%). Pooling of these trials showed no statistically significant difference in the risk of elevations more than 1.8 times ULN of ALT levels between AGIs treatment and control (Peto OR: 2.10, 95% CI 0.79 to 5.61; I-square = 51%). The subgroup analysis by dose of AGIs (AGIs ≤ 100 mg t.i.d. vs > 100 mg t.i.d.) showed a relatively apparent differential effects (interaction P = 0.02, Peto OR: 0.32 (0.05 to 1.97) vs 4.55 (1.42 to 14.58) (Fig. 4). The sensitivity analysis did not show important changes in the pooled effects.

Seven trials^{13–18,44} reported 17 cases elevations more than three times ULN of ALT levels occurred in 1611 patients who used at least one medication (raw event rate 1.0%). Pooling of these trials showed an increase in the risk of elevations more than three times ULN of ALT levels between AGIs treatment and control (Peto OR: 6.48, 95% CI 2.40 to 17.49; I-square = 0%) (Fig. 5). The subgroup analyses did not show any significant differences. The sensitivity analysis did not show important changes in the pooled effects, including the one analysis by removing studies with potential overlap of study population across publications (e.g. Chniff 1995a and Chniff 1995b).

Figure 2. The subgroup analyses by the varying doses of AGIs on the elevations 1.8-fold the upper limit of normal of AST levels.

Figure 3. Alpha-glucosidase inhibitors on the elevations 3-fold the upper limit of normal of AST levels in patients with type 2 diabetes.

Figure 4. The subgroup analyses by the varying doses of AGIs on the elevations 1.8-fold the upper limit of normal of ALT levels.

Discussion

In this study, we demonstrated the risk of hepatic AEs associated with AGIs use. Overall, the risk of developing hepatic AEs cannot be determined drawing from the 14 randomized trials, given the relatively small doses of

Figure 5. Alpha-glucosidase inhibitors on the elevations 3-fold the upper limit of normal of ALT levels in patients with type 2 diabetes.

acarbose (≤ 100 mg t.i.d), relatively small sample sizes and short follow-up. However, we found evidence showing increased risk of liver transaminases (AST and ALT) associated with the use of AGIs in patients with type 2 diabetes. In our study, there was a significant increase in odds of hepatotoxicity due to the elevation of AST and ALT. The odds of elevations greater than 3.0-fold ULN of AST and ALT levels were 6.86 and 6.48 times higher in patients receiving AGIs compared to patients in the control arms. For the pooling effects of elevations 1.8-fold ULN of AST and ALT, the results did not show a significant difference, but the subgroup analysis by dose of AGIs showed an apparent difference, which probably suggested that the risk of hepatotoxicity would be greatly increased when patients using AGIs more than 100 mg t.i.d. In addition, the study of Iwamoto¹⁸, which intervention was voglibose, showed no any changes in hepatic enzymes abnormalities (≥ 3 -fold ULN range) of AST and ALT. In addition, some studies^{4,13–17} reported that these elevations were asymptomatic and became normalized after discontinuation of the study medication. Combined the result of subgroup analysis by dose of AGIs using, it probably indicated that there exists dose-response relationship between the hepatotoxicity and AGIs exposure dose.

Little research was available to explore the hepatotoxicity induced by AGIs. One review⁷ about hepatotoxicity have been published in 2007. As part of this review regarding safety profile of acarbose, the content just described that acarbose may lead to hepatotoxicity, while not performing a rigorous and thorough analysis to evaluate the relationship between acarbose and risk of hepatotoxicity. In our study, we also searched the FDA Adverse Event Reporting System⁴⁶. The search yielded several cases of fatal hepatitis event in those using acarbose; however, additional information was unavailable. We also searched the US LiverTox website⁴⁷, and found no any information regarding voglibose and absence of clinical acute liver injury in those using miglitol. The website reported a case of acute liver cell damage in a patient administered with acarbose. Nevertheless, all of above information was based on case reports, which was unable to offer causality.

Our study has a few strengthens. First, it offers an up-to-date and complete overview of randomized controlled trials and observational studies concerning AGIs treatment. Though we included a number of RCTs, the data are relatively consistent and heterogeneity is acceptable. In addition to published reports, we searched ClinicalTrials.gov for completeness of data⁴⁸. In the meanwhile, one should interpret the findings cautiously because of limitations. First, many patients were withdrawal from these trials, possibly because of the side effect of gastrointestinal tract caused by AGIs, for which we were unable to account for⁷. Second, the reporting of hepatic AEs was lacking in many studies, leading to their exclusion from analysis. Adverse events, unlike efficacy outcomes, are rarely predetermined for systematic data collection in clinical trials. Therefore, reporting of adverse events depends highly on the investigators. Third, the type of reported hepatic AEs were highly variable, which made the collection and analysis of data challenging. Last, some studies^{14–16} have the potential overlap of study population across publications. We try to contact the author, but we can't get the contact information. Meanwhile, we have carefully checked the studies for potential overlap of study population across publications, and found that the study designs of these articles differed with each other (including total number of patients, number of groups, tested group, control group, and usage of medication). We also conducted a sensitivity analysis by removing these studies with potential overlap participants; the pooled estimates showed no significant changes, suggesting robustness of results to this potential issue.

In conclusion, our meta-analysis suggested that patients taking acarbose could have higher risk of liver damage compared to patients without AGIs. Although not definitive, the findings may suggest caution in the use of AGIs for those who are at high risk for hepatic dysfunction. In summary, although the effects of AGIs on hepatic AEs remain uncertain, the randomized evidence consistently suggests increased risk of liver enzymes elevation in general. Dose-response relationship may exist between the hepatotoxicity and AGIs dose.

Methods

Eligibility criteria. We included randomized controlled trials (RCTs) and observational studies (cohort studies and case-control studies) of patients with type 2 diabetes mellitus without any liver disease or abnormal liver transaminase that compared alpha-glucosidase inhibitors (acarbose, miglitol, voglibose) with placebo, lifestyle modification, or active antidiabetic agents. An eligible study should also follow up patients for at least 12 weeks (not applicable to case-control studies), and explicitly report outcome data regarding any hepatic AEs (e.g. hepatitis, death, liver transplantation, hospitalization for hepatotoxicity or withdrawal due to any liver damage), or high-grade alanine transaminase (ALT) and aspartate transaminase (AST).

High-grade ALT and AST elevations were defined as an elevation of more than 1.8-fold of the upper limit of normal (ULN)^{13–16,39,42,49,50}. These liver transaminases (AST or ALT) are useful biomarkers of liver injury in a patient with some degree of intact liver function^{50–52}.

Literature search. We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for reports published in English language from inception to July 2015. We combined both Medical Subject Headings (MeSH) and free text terms for identifying relevant articles. An information expert (JJY) helped develop the search strategy (Appendix 1). In our search, we included search terms defining AGIs and T2DM only, as we had planned to evaluate all the potential adverse events of AGIs, including – but not limited to – hepatotoxicity. We also searched ClinicalTrials.gov for additional information, which provides important data on hepatotoxicity.

Study process. Two reviewers, trained in health research methods, independently screened titles/abstracts and full texts for eligibility, assessed risk of bias, and collected data from each eligible study, using standardized, pilot-tested forms, together with detailed instructions. Reviewers resolved disagreement through discussion or, if required, adjudication by a third reviewer.

Risk of bias assessment. We assessed the risk of bias of RCTs using the Cochrane Collaboration's tool⁵³. The items included random sequence generation, allocation concealment, blinding of participants, caregivers, and assessors of outcomes (i.e. hepatitis or changes in liver enzymes), incomplete outcome data, prognostic balance between treatment groups, selective reporting. We planned to assess the risk of bias of observational studies using the Newcastle–Ottawa Quality Assessment Scale⁵⁴.

Data collection. We collected the following information from each study: study characteristics (authors' name, year of publication, total number of patients randomized, number of treatment groups, length of follow-up, funding source, countries involved, and number of study sites); patient characteristics (gender, age, diabetes duration, body mass index (BMI), baseline HbA1c level, and fasting plasma glucose); interventions (medications common to all groups (baseline treatment, details of AGIs therapy and control group); and outcomes (any hepatic adverse events occurred during the course of study). For RCTs, if the initial treatment assignment was switched (e.g. patients in placebo group started receiving AGIs agents after 24 weeks), we collected the data prior to that point. If a trial had multiple reports, we collated all data into a single study⁵⁵. If the outcome data were reported in multiple follow up points, we used data with the longest follow-up.

Data analysis. We planned to analyze RCTs and observational studies separately. However, no observational studies were eligible. For randomized trials, we pooled the data using Peto's methods because of the very low event rate⁵⁵, and reported pooled Peto ORs and associated 95% CIs. We examined the heterogeneity among studies by the Cochran chi-square test and the I-squared statistic. We explored sources of heterogeneity with three priori subgroup hypotheses: type of AGIs agent (acarbose; miglitol and voglibose); type of control (AGIs vs placebo, AGIs vs active treatment); dose of AGIs using (AGIs ≤ 100 mg t.i.d. and >100 mg t.i.d.); length of follow-up (≤ 26 weeks and >26 weeks) and mode of treatment (AGIs monotherapy, AGIs add-on/combo treatment). We carried out sensitivity analyses by using alternative effect measures (odds ratio (OR) vs. risk ratio (RR)), pooling methods (Peto vs. Mantel-Haenszel method), statistical models regarding heterogeneity (random vs. fixed effects), and removal of studies with potential overlap of study populations across publications.

We planned to examine publication bias by the funnel plot or other methods (such as Egger's and Begg's). Because of the low power of test associated with studies of low events rate, we were unable to examine this. We reported the results according to preferred reporting items for systematic reviews and meta-analyses (PRISMA)⁵⁶.

References

1. Yang, W. *et al.* Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. *The Lancet Diabetes & Endocrinology*. **2**, 46–55, doi: 10.1016/s2213-8587(13)70021-4 (2014).
2. Li, Y. *et al.* Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis. *International journal of clinical practice*. **68**, 1318–1332, doi: 10.1111/ijcp.12467 (2014).
3. Stephen, P. & Clissold, C. E. Acarbose. *Drugs*. **25**, 214–243 (1988).
4. Silvio, E., Inzucchi R. M. B. *et al.* Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. **38**, 140–149, doi: 10.2337/dc14-2441/-/DC1 (2015).
5. Chiasson, J.-L. *et al.* Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *The Lancet*. **359**, 2072–2077, doi: 10.1016/s0140-6736(02)08905-5 (2002).
6. Chiasson, J. L., J. R., Gomis, R., Hanefeld, M., Karasik, A. & Laakso, M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA*. **290**, 486–494 (2003).
7. Hanefeld, M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. *Cardiovasc Diabetol*. **6**, 20, doi: 10.1186/1475-2840-6-20 (2007).
8. van de Laar, F. A. *et al.* Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care*. **28**, 154–163 (2005).
9. Gentile, S. T. S., Guarino, G., Sasso, F. C. & Torella, R. Aminotransferase activity and acarbose treatment in patients with type 2 diabetes. *Diabetes Care*. **22**, 1217–1218 (1999).
10. Carrascosa, M. P. F. & Aresti S. Acarbose-induced acute severe hepatotoxicity. *Lancet*. **349**, 698–699 (1997).
11. Andrade, R. J. L. M. & Rodriguez-Mendizabal, M. Hepatic injury caused by acarbose. *Ann Intern Med*. **124**, 931 (1996).
12. P. H., Safety profile of acarbose, an alpha-glucosidase inhibitor. *Drugs*. **44**, 47–53 (1992).
13. Coniff, R. F., Shapiro J. A. & Seaton T. B. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. *Archives of internal medicine*. **154**, 2442–2448 (1994).

14. Coniff, R. F. *et al.* Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. *Diabetes Care*. **18**, 817–824 (1995).
15. Coniff R. F., Shapiro J. A., Seaton T. B. & Bray G. A. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. *The American journal of medicine*. **98**, 443–451, doi: 10.1016/s0002-9343(99)80343-x (1995).
16. Coniff, R. F. *et al.* A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. *Diabetes Care*. **18**, 928–932 (1995).
17. Lam, K. S. *et al.* Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. *Diabetes Care*. **21**, 1154–1158 (1998).
18. Iwamoto, Y. *et al.* Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. *Diabetes, obesity & metabolism*. **12**, 700–708, doi: 10.1111/j.1463-1326.2010.01222.x (2010).
19. Chang, C. H. *et al.* Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: A nationwide cohort study. *Journal of Clinical Endocrinology and Metabolism*. **100**, 1121–1129 (2015).
20. Tsilidis, K. K. *et al.* Metformin does not affect cancer risk: A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial. *Diabetes Care*. **37**, 2522–2532 (2014).
21. Ou, H. T. & Chen Y. T. Comparative effectiveness research of metformin-based oral hypoglycemic therapy in taiwan's population-based database. *Pharmacoepidemiology and Drug Safety*. **23**, 241–242 (2014).
22. Lin, H. C. *et al.* Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: A six-year population-based cohort study. *Journal of Clinical Pharmacy and Therapeutics*. **39**, 354–360 (2014).
23. Faillie, J. L. *et al.* Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: Cohort study. *BMJ (Online)*. **348**, doi: 10.1136/bmj.g2780 (2014).
24. Chen, J. M. *et al.* Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: A nationwide seven-year follow-up study. *Journal of Diabetes Research*. **2014**, doi: 10.1155/2014/812628 Epub 2014 Jul 7 (2014).
25. Chen, J. M. *et al.* Effects of statins on incident dementia in patients with type 2 DM: A population-based retrospective cohort study in Taiwan. *PLoS ONE*. **9**, e88434, doi: 10.1371/journal.pone.0088434. eCollection 2014 (2014).
26. Zhang, W. *et al.* A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study. *Clinical Drug Investigation*. **33**, 263–274 (2013).
27. Hwang, A. L., Haynes, K., Hwang, W. T. & Yang, Y. X. Metformin and survival in pancreatic cancer: A retrospective cohort study. *Pancreas*. **42**, 1054–1059 (2013).
28. Dickman, R. *et al.* Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. *Journal of Diabetes and its Complications*. **27**, 376–379 (2013).
29. Antoniou, T. *et al.* Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: A population-based cohort study. *Cmaj*. **185**, 1035–1041 (2013).
30. Tseng, C. H. Diabetes, insulin use and *Helicobacter pylori* eradication: A retrospective cohort study. *BMC Gastroenterology*. **12**, doi: 10.1186/1471-230X-12-46 (2012).
31. Best, J. D. *et al.* Glycemic control over 5 years in 4,900 people with type 2 diabetes: Real-world diabetes therapy in a clinical trial cohort. *Diabetes Care*. **35**, 1165–1170 (2012).
32. Lewis, J. D. *et al.* Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. *Diabetes Care*. **34**, 916–922 (2011).
33. Ziyadeh, N. *et al.* The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database. *Clinical Therapeutics*. **31**, 2665–2677 (2009).
34. Monami, M. *et al.* Sulphonylureas and cancer: A case-control study. *Acta Diabetologica*. **46**, 279–284 (2009).
35. Juurlink, D. N. *et al.* Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population based cohort study. *BMJ (Online)*. **339**, 562, doi: 10.1136/bmj.b2942 (2009).
36. Maru, S. *et al.* Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. *Diabetes Care*. **28**, 20–26 (2005).
37. Landgraf, R., Frank, M., Bauer, C. & Leyck Dieken, M. Prandial glucose regulation with repaglinide: Its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes. *International Journal of Obesity*. **24**, S38–S44 (2000).
38. Costa, B. & Pinol, C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: A randomised- multicentric trial in primary health-care. *Diabetes Research and Clinical Practice*. **38**, 33–40 (1997).
39. Fischer, S. *et al.* European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. *Acta Diabetol*. **35**, 34–40 (1998).
40. Gentile, S. *et al.* Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. *Diabetes, obesity & metabolism*. **3**, 33–40 (2001).
41. Hoffmann, J. & Spengler, M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. *The American journal of medicine*. **103**, 483–490 (1997).
42. Hwu, C. M. *et al.* Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. *Diabetes Res Clin Pract*. **60**, 111–118 (2003).
43. Johnston, P. S. *et al.* Effects of the carbohydrate inhibitor miglitol in sulfonylurea-treated NIDDM patients. *Diabetes Care*. **17**, 20–29 (1994).
44. Rosenstock, J. *et al.* Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. *Diabetes Care*. **21**, 2050–2055 (1998).
45. Scorpiglione, N. *et al.* The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence. *European journal of clinical pharmacology*. **55**, 239–249 (1999).
46. U.S. Department of Health and Human Services. U.S. Food and Drug Administration, Precose (acarbose) Tablets Prescribing Information. [Safety Information] <http://www.fda.gov/safety/medwatch/safetyinformation/ucm250694.htm>. Page Last Updated: 04/15/2015 (2015).
47. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). LiverTox, Clinical and Research information on Drug-induced liver injury-Acarbose. [Drug Record] <http://livertox.nlm.nih.gov/Acarbose.htm#casereport>. Last updated: 2016-03-24 01:30:41 PM (EST) (2016).
48. Li, L. *et al.* Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. *BMJ*. **348**, g2366, doi: 10.1136/bmj.g2366 (2014).
49. David, E. & Johnston, M. D. Special Considerations in Interpreting Liver Function Tests. *Am Fam Physician*. **59**, 2223–2230 (1999).
50. Mengel, M. B. S. & Peter, L. *Family medicine: ambulatory care & prevention*. McGraw-Hill Professional. pp. 268–ISBN 978-0-07-142322-9 (2005).
51. DE, J. Special considerations in interpreting liver function tests. *Am Fam Physician*. **59**, 2223–2230 (1999).
52. McClatchey, K. D. *Clinical laboratory medicine*. Lippincott Williams & Wilkins. pp. 288–. ISBN 978-0-683-30751-1. Retrieved 5 August 2011 (2002).
53. Higgins, J. P. T. AD S. J. Assessing risk of bias in included studies. In: Higgins J. P. T., Green S, eds. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0. Cochrane Collaboration (2011).

54. Wells, G. A. S. B., O'Connell D., Peterson J., Welch V., Losos M. *et al.* The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized *Studies in Meta-Analysis*. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed May 25 2015). (2015).
55. Higgins, J. P. T. & Deeks, J. J. A. D. Special topics in statistics. In: Higgins, J. P. T. & Green, S., eds. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0. *Cochrane Collaboration* (2011).
56. Stroup, D. F. B. J., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D. *et al.* Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. *JAMA* **283**, 2008–2012 (2000).

Acknowledgements

We thank Jiajie Yu for developing the search strategy. This study was supported by National Natural Science Foundation of China (Grant No. 71573183), “Thousand Youth Talents Plan” of China (Grant No: D1024002) and Sichuan Province, and Young Investigator Award of Sichuan University (Grant No: 2013SCU04A37). These funders had no role in the study design, writing of the manuscript, or decision to submit this or future manuscripts for publication.

Author Contributions

X.S. and M.Z. conceived the study. X.S. acquired the funding. L.Z. and Q.C. had full access to all of the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis. L.Z. and Q.C. developed and tested the data collection forms. L.Z., Q.C., P.J. and P.Z. acquired the data. L.Z. and L.L. conducted the analysis and interpreted the data. L.Z., Q.C. and M.Z. drafted the manuscript. M.Z., L.L., J.S.W.K., W.W., X.Z. and X.S. revised the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhang, L. *et al.* Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. *Sci. Rep.* **6**, 32649; doi: 10.1038/srep32649 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016